We continue our discussion about Brian Pace and Neşe Devenot's recently published paper: "Right-Wing Psychedelia: Case Studies in Cultural Plasticity and Political Pluripotency" 

We talk drugs and anti-capitalism with anthropology PhD candidate, Hilary Agro. Ranging from prohibition to psychedelic clinical trials and beyond, we explore the overlaps and differences in our analyses of the current psychedelic (and broader drug policy) landscape.

We kicked off the start of our ongoing livestreams with the announcement of Psymposia's 501(c)(3) non-profit status, discussions of corporadelic dynamics, fond memories of helping people learn how to extract psychedelic drugs during an Ivy League University's psychedelic conference, and a whole bunch of back and forth with the audience about the current state (and future) of psychedelia.

We kicked off the start of our ongoing livestreams with the announcement of Psymposia's 501(c)(3) non-profit status, discussions of corporadelic dynamics, fond memories of helping people learn how to extract psychedelic drugs during an Ivy League University's psychedelic conference, and a whole bunch of back and forth with the audience about the current state (and future) of psychedelia.

Can psychedelic civil disobedience really stimulate systemic reorganization?

For decades, MAPS and other proponents of psychedelic medicalization have justified their emphasis on treating police and soldiers as a political strategy in service to mainstreaming psychedelic drugs. This strategy perpetuates the logic of white supremacism, capitalism, and imperialism.

As technology and psychedelics turn to mental health, we’ll likely see a future where we are treated based on our digital biomarkers, and sold mental health services based on the personal data we surrender.

Psychedelic capitalists justify their decision to go for-profit in the ballroom of America’s most recent for-profit flop.

After decades of psychedelic nonprofits paving regulatory pathways and priming wealthy investors, for-profits are moving in to reap the rewards.

The new leaders of the psychedelic medicalization industry seem to see themselves as above their own self-proposed rules.